Department of Stomatology, The Second People's Hospital of Changzhi, Changzhi, Shanxi, China.
Department of Stomatology, Mudanjiang Medical University, Mudanjiang, Heilongjiang, China.
Medicine (Baltimore). 2022 Jun 24;101(25):e29393. doi: 10.1097/MD.0000000000029393.
Inflammation is hypothesized to contribute to the pathogenesis of periodontitis. Resveratrol (RV) is known for its anti-inflammatory properties. The purpose of this study was to investigate the inhibitory effect of RV on local inflammatory markers and systemic endotoxin in patients with periodontitis.
A total of 160 patients with periodontitis were enrolled in this study. The selected patients were randomly divided into four groups and received placebo, high-dose (500 mg/d) of RV (HRV, n = 40), middle-dose (250 mg/d) of RV (middle dose RV (MRV), n = 40) and low-dose (125 mg/d) of RV (low dose RV (LRV), n = 40) with orally administration. All patients received an 8-week treatment. The periodontal status of patients with periodontitis was recorded by using clinical attachment level (CAL), bleeding index (BI), oral hygiene index-simplified (OHI-S), and probing pocket depth (PPD). The levels of inflammatory markers in serum and gingival crevicular fluid (GCF), and systemic levels of endotoxin were evaluated using high sensitivity enzyme-linked immuno sorbent assay.
Outcomes showed that symptoms of periodontitis determined by CAL, BI OHI-S and PPD were improved by RV compared to placebo. RV treatment decreased inflammatory markers in serum and GCF compared to placebo in patient with periodontitis. Systemic endotoxin declined more in the RV group than the placebo-treated group.
In conclusion, data in the current study indicate that RV is an efficient drug for the treatment of patients with periodontitis. The findings of the present study find that RV inhibits systemic local inflammatory markers and systemic endotoxin and suggest that 500 mg/d RV is the ideal dose for patients with periodontitis.
炎症被认为是牙周炎发病机制的一个因素。白藜芦醇（RV）以其抗炎特性而闻名。本研究旨在探讨 RV 对牙周炎患者局部炎症标志物和全身内毒素的抑制作用。
本研究共纳入 160 例牙周炎患者。入选患者随机分为四组，分别给予安慰剂、高剂量（500mg/d） RV（HRV，n=40）、中剂量（250mg/d） RV（中剂量 RV（MRV），n=40）和低剂量（125mg/d） RV（低剂量 RV（LRV），n=40）口服治疗。所有患者均接受 8 周治疗。采用临床附着水平（CAL）、出血指数（BI）、简化口腔卫生指数（OHI-S）和探诊袋深度（PPD）记录牙周炎患者的牙周状况。采用高敏酶联免疫吸附试验评估血清和龈沟液（GCF）中炎症标志物及全身内毒素水平。
结果显示，与安慰剂相比，RV 可改善 CAL、BI、OHI-S 和 PPD 确定的牙周炎症状。RV 治疗可降低牙周炎患者血清和 GCF 中的炎症标志物，与安慰剂相比。与安慰剂组相比，RV 组全身内毒素下降更多。
综上所述，本研究数据表明 RV 是治疗牙周炎患者的有效药物。本研究发现 RV 抑制全身局部炎症标志物和全身内毒素，并提示 500mg/d RV 是牙周炎患者的理想剂量。
